| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Malcolm Brenner | Q6742199 |
| Siok-Keen Tey | Q61051395 | ||
| P2860 | cites work | Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation | Q44618759 |
| Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes | Q45551744 | ||
| Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy | Q45733496 | ||
| Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes | Q45771097 | ||
| Polyclonal long-term repopulating stem cell clones in a primate model | Q45855127 | ||
| T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients | Q45876112 | ||
| Detection and direct genomic sequencing of multiple rare unknown flanking DNA in highly complex samples | Q45876897 | ||
| Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients | Q45884043 | ||
| In vivo migration and function of transferred HIV-1-specific cytotoxic T cells | Q47995100 | ||
| Gene-marking to trace origin of relapse after autologous bone-marrow transplantation | Q49158499 | ||
| Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin. | Q54180724 | ||
| Retrovirus-mediated gene transfer as an approach to analyze neuroblastoma relapse after autologous bone marrow transplantation. | Q54273250 | ||
| Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. | Q54662841 | ||
| Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones | Q67518698 | ||
| Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report | Q68100559 | ||
| In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma | Q69789630 | ||
| Retroviral gene transfer in autologous bone marrow transplantation for adult acute leukemia | Q71561998 | ||
| Use of double marking with retroviral vectors to determine rate of reconstitution of untreated and cytokine expanded CD34+ selected marrow cells in patients undergoing autologous bone marrow transplantation | Q71624183 | ||
| Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission | Q72103186 | ||
| Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients | Q72656870 | ||
| Safety of retroviral gene marking with a truncated NGF receptor | Q73200787 | ||
| Is retroviral gene marking too dangerous to use? | Q73635243 | ||
| Murine leukemia induced by retroviral gene marking | Q77975543 | ||
| Engraftment of gene-marked hematopoietic progenitors in myeloma patients after transplant of autologous long-term marrow cultures | Q78191043 | ||
| Cancer regression in patients after transfer of genetically engineered lymphocytes | Q24654976 | ||
| Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes | Q24676216 | ||
| LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 | Q28210584 | ||
| Side effects of retroviral gene transfer into hematopoietic stem cells | Q34168349 | ||
| Gene-marking studies of hematopoietic cells | Q34261323 | ||
| Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. | Q34334845 | ||
| Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction | Q34354588 | ||
| Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial | Q34533140 | ||
| Genetically modified pigs produced with a nonviral episomal vector | Q34581389 | ||
| Stem cells and repair of the heart. | Q35832759 | ||
| Efficient marking of human cells with rapid but transient repopulating activity in autografted recipients | Q35847936 | ||
| Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation | Q35849500 | ||
| A procedure for in vitro amplification of DNA segments that lie outside the boundaries of known sequences | Q36064468 | ||
| Towards safe, non-viral therapeutic gene expression in humans. | Q36068277 | ||
| Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation | Q36104468 | ||
| Gene therapy imaging in patients for oncological applications. | Q36265644 | ||
| Cell-based therapies and imaging in cardiology | Q36277263 | ||
| Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease | Q36399791 | ||
| Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes | Q36404076 | ||
| Cardiac Stem Cell Therapy. Need for Optimization of Efficacy and Safety Monitoring | Q36545640 | ||
| In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial | Q37350605 | ||
| Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma | Q40280252 | ||
| Retroviral vector insertions in T-lymphocytes used for suicide gene therapy occur in gene groups with specific molecular functions | Q40314396 | ||
| Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors | Q40338282 | ||
| Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes | Q40565585 | ||
| Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes | Q40662000 | ||
| Gene-marking and haemopoietic stem-cell transplantation | Q41137652 | ||
| Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma | Q41656230 | ||
| Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of graft-versus-host disease | Q42168145 | ||
| Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial | Q42642159 | ||
| A novel 'sort-suicide' fusion gene vector for T cell manipulation | Q44211391 | ||
| Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates | Q44364376 | ||
| Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma | Q44449180 | ||
| P433 | issue | 4 | |
| P921 | main subject | gene therapy | Q213901 |
| P304 | page(s) | 666-676 | |
| P577 | publication date | 2007-02-13 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | The continuing contribution of gene marking to cell and gene therapy | |
| P478 | volume | 15 |
| Q34511623 | Adoptive T-cell therapy: adverse events and safety switches |
| Q37919127 | Genome walking in eukaryotes. |
| Q36986958 | Insertional mutagenesis and clonal dominance: biological and statistical considerations |
| Q37089345 | In Vivo Tracking of Human Hematopoiesis Reveals Patterns of Clonal Dynamics during Early and Steady-State Reconstitution Phases |
| Q38508008 | Lentiviral gene ontology (LeGO) vectors equipped with novel drug-selectable fluorescent proteins: new building blocks for cell marking and multi-gene analysis. |
| Q34645099 | Nontoxic genetic engineering of mesenchymal stem cells using serum-compatible pullulan-spermine/DNA anioplexes |
| Q36453570 | Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials |
| Q91587859 | Recent Advances in the Development of Bio-Reducible Polymers for Efficient Cancer Gene Delivery Systems |
| Q33712953 | Stem cell marking with promotor-deprived self-inactivating retroviral vectors does not lead to induced clonal imbalance |
Search more.